Establishment of

Baltic Biomaterials Centre of Excellence

Rīga Stradiņš University (RSU) is the leading academic and research institution in the field of medicine, pharmacy, dentistry, rehabilitation, and nursing sciences in Latvia. RSU is ranked by QS among top 1000 universities in the world, with the highest rating in international student ratio and academic reputation. The University has close affiliation with leading hospitals in Latvia and experience in EU FP7, Horizon 2020, COST, ERA-NET, Interreg and national research projects. RSU uses a modern quality improvement approach to ensure high study and research quality. In 2017, the quality management system of the University was recertified in accordance with ISO 9001:2015 and received ISO 50001 certificate to comply with the energy management system international standard.

Currently, RSU Faculty of Pharmacy is running a project to set up a new Finished Dosage Form R&D Laboratory (FDF Lab) to promote research in pharmaceutical sciences. It is planned that the Lab will be set up in 2022 and it will gradually expand its research area from oral solid dosage forms (tablets, capsules, granules) to biomaterials to explore kinetics (drug releasing profile) and stability of drug delivery systems. The FDF Lab will use its analytical capacity and infrastructure for dissolution testing, spectroscopy, chromatography, mass spectrometry, and microscopy among other techniques. The Lab will be also involved in material characterization, processing, and quality control of the finished products.

BBCE project´s main objective is to establish a joint Baltic Biomaterials Centre of Excellence for advanced biomaterials development based on the long-term strategic cooperation between AO Research Institute Davos, Switzerland (ARI) and Friedrich-Alexander University of Erlangen-Nuremberg, Germany (FAU) on the one hand and RTU RBIDC, LIOS and RSU on the other hand.



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 763721